### Highlights of This Issue  567

#### REVIEW

569  |  Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment  
Enrique Grande, Maria-Victoria Bolós, and Edurne Arriola  

637  |  Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer  
Yuh-Pyng Sher, Shih-Jen Liu, Chun-Mien Chang, Shu-Pei Lien, Chien-Hua Chen, Zhenbo Han, Long-Yuan Li, Jin-Shing Chen, Cheng-Wen Wu, and Mien-Chie Hung  

### THERAPEUTIC DISCOVERY

580  |  GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer  
Hyun Sook Kang, Tsukasa Baba, Masaki Mandai, Noriomi Matsumura, Junzo Hamanishi, Budiman Kharma, Eiji Kondoh, Yumiko Yoshioka, Shinya Oishi, Nobutaka Fujii, Susan K. Murphy, and Ikuo Konishi  

648  |  Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer  
Holly Symolon, Anatoliy Bushnev, Qiong Peng, Harsha Ramaraju, Suzanne G. Mays, Jeremy C. Allegood, Sarah T. Pruett, M. Cameron Sullards, Dirck L. Dillehay, Dennis C. Liotta, and Alfred H. Merrill, Jr.  

658  |  Targeting the ReplicationCheckpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening  
Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Frances Shanahan, Nicole Davis, Lorena Taricani, Derek Wiswell, Wolfgang Seghezzi, Ervin Penafior, Bhagyashree Bhagwat, Wei Wang, Danling Gu, Yunsheng Hsieh, Suining Lee, Ming Liu, and David Parry  

669  |  Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy  
Seung-Uon Shin, Hyun-Mi Cho, Jaime Merchan, Jin Zhang, Krisztina Kovacs, Yawu Jing, Sundaram Ramakrishnan, and Joseph D. Rosenblatt  

### PRECLINICAL DEVELOPMENT

670  |  Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor  
Hiroyoshi Hattori, Ferdinandos Skoulidis, Paul Russell, and Ashok R. Venkitaraman  

679  |  Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus–Related Burkitt’s Lymphoma  
Osman Cen and Richard Longnecker
Gene Expression Profiling Provides Insights into Pathways of Oxaliplatin-Related Sinusoidal Obstruction Syndrome in Humans
Laura Rubbia-Brandt, Sébastien Tauzin, Catherine Brezault, Céline Delucinge-Vivier, Patrick Descombes, Bertrand Dousset, Pietro E. Majno, Gilles Mentha, and Benoit Terris

Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

Correction: Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38

ABOUT THE COVER
Genetically-engineered mouse models often represent some of the most physiologically accurate models of cancer from which to understand the tumor microenvironment and with which to perform preclinical trials. Abraham and colleagues present studies of a prototypic insulin-like growth factor receptor inhibitor using both genetically-engineered mouse models and the shell-free quail chorioallantois membrane (CAM) assay. Remarkably, the inexpensive short term (2 week) CAM assay offers xenografted tumors a scaffold of lymphatics, arteries, and veins that mimic short-term in vivo growth with all the advantages of intravital imaging. Photograph credits, Elaine Huang and Audra Lee. For details, see article by Abraham and colleagues on page 697.